First-line cisplatin (P) with docetaxel (TXT) or vinorelbine (VNR) in patients with advanced non-small cell lung cancer: A randomized phase II trial of the Gruppo Oncologico Italia Meridionale
Vittorio Gebbia(Università degli Studi di Enna Kore), Saverio Cinieri(Ospedale A. Perrino), Vito Lorusso(Istituto Tumori Bari), Evaristo Maiello(Casa Sollievo della Sofferenza), Francesco Ferraù(Université Paris-Sud), Giuseppe Colucci(Roche (Switzerland)), Michele Caruso(Humanitas Mater Domini), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Nicolò Borsellino(Ospedale Buccheri la Ferla Fatebenefratelli), Domenico Galetta(Istituto Tumori Bari)
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial
|JNCI Journal of the National Cancer Institute|2003|795
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743